SCHEDULE: OrbiMed Reports Zero Stake in Vistagen Therapeutics
Beneficial Ownership Filing Amendment
OrbiMed Advisors LLC and OrbiMed Capital LLC have filed an amendment reporting zero shares beneficially owned in Vistagen Therapeutics, Inc.
Summary
- OrbiMed Advisors LLC and OrbiMed Capital LLC have filed an amendment to their Schedule 13G, reporting a change in their beneficial ownership of Vistagen Therapeutics, Inc. common stock.
- As of June 30, 2026, both entities report holding 0 shares, representing 0.0% of the class of securities.
- This filing indicates a complete divestment or lack of any beneficial ownership by OrbiMed in Vistagen Therapeutics.
- The reporting persons disclaim beneficial ownership of any shares held on behalf of other persons.
Sentiment
Score: 2
Explanation: StockSavvy.ai views this as a negative score due to the reporting of zero beneficial ownership, indicating a complete divestment or lack of current stake by the reporting entities.
Negatives
- OrbiMed Advisors LLC and OrbiMed Capital LLC now report 0 shares beneficially owned in Vistagen Therapeutics, Inc.
- This signifies a complete reduction of their stake in the company to zero percent.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Management Comments
- Carl L. Gordon, Member of OrbiMed Advisors LLC and OrbiMed Capital LLC, certified that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that a Schedule 13G filing typically indicates passive investment. The complete divestment reported by OrbiMed, a significant healthcare-focused investment firm, could signal a change in their investment thesis or a strategic reallocation of capital away from Vistagen Therapeutics.
Stakeholder Impact
- Shareholders may interpret this divestment as a negative signal regarding OrbiMed's confidence in Vistagen Therapeutics' future prospects, potentially impacting share price.
Key Dates
| Date | Description |
|---|---|
| 06/30/2026 | Date of Event Which Requires Filing of this Statement |
| 08/14/2026 | Date of execution of Joint Filing Agreement and certification of filing. |
Keywords
Vistagen Therapeutics, OrbiMed Advisors, OrbiMed Capital, Schedule 13G, Beneficial Ownership, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.